ArticleJournal of medical biochemistry2026
Trends in pregabalin misuse and abuse: A 25-year bibliometric perspective.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Originally classified among antiepileptic drugs, pregabalin has been prescribed for clinical conditions such as neuropathic pain, generalised anxiety disorder, and fibromyalgia. In recent years, accumulating evidence has highlighted its potential for misuse and abuse, particularly among individuals with a high prevalence of opioid dependence. This study aims to conduct a comprehensive bibliometric analysis of global research on pregabalin misuse and abuse, to identify key trends, influential contributors, and collaborative networks. Methods: Bibliometric design was employed using data retrieved from the Web of Science Core Collection database. The search was conducted in February 2025, and relevant publications were identified based on predefined inclusion and exclusion criteria. A total of 449 eligible records were exported and compiled for analysis. The bibliometric analysis was carried out using the bibliometrix R package and its Web-based interface Biblioshiny, both operating within the RStudio environment. Results: The analysis revealed a notable increase in scientific output on pregabalin misuse and dependence, particularly after 2010. The United States emerged as the most prolific and central country within the global collaboration network, followed by the United Kingdom, Germany, and France. Leading authors and institutions were concentrated in specific academic clusters. Keywords such as "abuse," "addiction," and "opioids" have shown an increasing trend since 2016. Conclusions: This study highlights the growing academic interest in the misuse and abuse potential of pregabalin, particularly over the past decade. The findings reveal a centralised research structure, with significant contributions from high-capacity countries such as the United States, the United Kingdom, and Germany. Emerging participation from developing countries, including Türkiye, underscores a broadening global awareness of the issue. The results emphasise the importance of interdisciplinary collaboration, policies, and the critical role of clinical laboratories in monitoring pregabalin-related risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.